调脂汤对痰瘀阻络型冠心病心绞痛患者血脂异常达标率的临床疗效观察

发布时间：2018-06-21 21:19

本文选题：调脂汤 + 痰瘀阻络型　；参考：《南京中医药大学》2017年硕士论文

【摘要】：目的:观察调脂汤治疗痰瘀阻络型冠心病心绞痛合并血脂异常患者的疗效及安全性,为临床提供新的思路和方法。方法:选取2016年4月至2017年1月在徐州市中医院就诊的痰瘀阻络型冠心病合并血脂异常的住院患者60例。将患者按随机表法分组,分为对照组31例,采用常规西医方案:阿司匹林肠溶片、琥珀酸美托洛尔缓释片、单硝酸异山梨酯片、阿托伐他汀钙等治疗;治疗组29例,在对照组基础上加服自拟调脂汤。两组共服药30天,观察结束后,比较两组治疗前后相关血脂指标、超敏C反应蛋白、中医证候积分和安全性指标的改变。运用SPSS 19.0统计软件进行结果分析。结果:治疗后两组相关血脂指标均降低,治疗组与对照组相比较,血脂指标降低更为明显,差异有统计学意义(P0.05),且治疗组总有效率高于对照组,亦存在统计学差异(P0.05);两组均能降低超敏C反应蛋白水平,但两组疗效差异无统计学意义(P0.05);两组中医症候积分较前均有所改善,且治疗组优于对照组,差异有统计学意义(P0.05);两组治疗前后安全性指标无明显改变,两组对比差异无统计学意义(P0.05)。结论:调脂汤联合西药可以改善痰瘀阻络型冠心病心绞痛合并血脂异常患者的临床症状,显著降低血脂,安全性较好,适合临床推广。
[Abstract]:Objective: to observe the efficacy and safety of Tiaozhi decoction in the treatment of angina pectoris complicated with dyslipidemia in patients with phlegm and stagnation of collaterals. Methods: from April 2016 to January 2017, 60 cases of coronary heart disease complicated with dyslipidemia of phlegm and blood stasis were selected from Xuzhou Hospital of traditional Chinese Medicine. The patients were randomly divided into control group (n = 31) and control group (n = 31) treated with aspirin enteric-coated tablets, metoprolol succinate sustained-release tablets, isosorbide mononitrate tablets, Atto vastatin calcium, etc. In the control group on the basis of the addition of self-made Tiaozhi decoction. The changes of blood lipid index, hypersensitive C-reactive protein, TCM syndromes score and safety index were compared before and after treatment. The results were analyzed by SPSS 19.0 software. Results: compared with the control group, the blood lipid index of the treatment group was lower than that of the control group, the difference was statistically significant (P 0.05), and the total effective rate of the treatment group was higher than that of the control group. There was also a statistical difference between the two groups (P 0.05). Both groups could reduce the level of hypersensitive C-reactive protein, but there was no significant difference in curative effect between the two groups (P 0.05). The scores of TCM symptoms in the two groups were improved compared with the former, and the treatment group was better than the control group. The difference was statistically significant (P 0.05), and there was no significant change in the safety index before and after treatment between the two groups, but there was no significant difference between the two groups (P 0.05). Conclusion: Tiaozhi decoction combined with western medicine can improve the clinical symptoms of angina pectoris complicated with dyslipidemia in patients with phlegm and stasis obstruction angina pectoris and dyslipidemia. It is safe and suitable for clinical application.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259

【参考文献】